RxDoctor Payments Data

Eric Isenman, MD

Internal Medicine · Melbourne, FLNPI 1609931187

Payments from drug & device makers

$807in general payments, 2019–2025

Across 48 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$179
  • Phathom Pharmaceuticals, Inc.$129
  • Amgen$107
  • Boehringer Ingelheim$69
  • AstraZeneca$55
  • Lilly USA, LLC$53
  • plus $214 from 9 others

What the payments were for

  • Food & beverage$807100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$807 in reported general payments places this provider in the 65th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$346,974
Medicare patients
525
Services billed
7,255

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban230$144,640
OzempicSemaglutide74$97,876
JardianceEmpagliflozin90$86,312
XareltoRivaroxaban44$47,711
GlyxambiEmpagliflozin/Linagliptin27$23,439
MounjaroTirzepatide20$23,053
FarxigaDapagliflozin Propanediol37$21,485
EntrestoSacubitril/Valsartan18$19,249
Dabigatran EtexilateDabigatran Etexilate Mesylate50$16,828
Testosterone32$16,604
CreonLipase/Protease/Amylase14$14,269
MultaqDronedarone Hcl14$14,064
LinzessLinaclotide14$13,635
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$12,198
Atorvastatin Calcium717$11,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$28$144,640230 claims
Boehringer IngelheimJardiance, Glyxambi$69$109,751117 claims
Novo NordiskOzempic$179$97,87674 claims
Johnson & JohnsonXarelto$13$47,71144 claims
AbbVieCreon, Linzess, Synthroid$36$32,15281 claims
Lilly USA, LLCMounjaro$53$23,05320 claims
AstraZenecaFarxiga$55$21,48537 claims
NovartisEntresto$52$19,24918 claims
Sanofi-aventis U.S. LLCMultaq$12$14,06414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →